NASDAQ:ENTX - Nasdaq - IL0011429839 - Common Stock - Currency: USD
NASDAQ:ENTX (4/28/2025, 8:05:18 PM)
2.28
-0.12 (-5%)
The current stock price of ENTX is 2.28 USD. In the past month the price increased by 30.29%. In the past year, price increased by 5.56%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 18.73 | 340.25B | ||
AMGN | AMGEN INC | 14.28 | 152.20B | ||
GILD | GILEAD SCIENCES INC | 13.74 | 132.57B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1712.03 | 127.64B | ||
REGN | REGENERON PHARMACEUTICALS | 13.38 | 66.78B | ||
ARGX | ARGENX SE - ADR | 326.83 | 37.92B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 33.15B | ||
ONC | BEIGENE LTD-ADR | N/A | 26.88B | ||
BNTX | BIONTECH SE-ADR | N/A | 25.00B | ||
NTRA | NATERA INC | N/A | 20.68B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.78B | ||
BIIB | BIOGEN INC | 7.23 | 17.44B |
Entera Bio Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of orally delivered large molecule therapeutics. The firm developed a platform that enables the oral delivery of injectable proteins and large molecules. Entera Bio candidates are EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism. Both EB613 and EB612 are oral formulations of human parathyroid hormone (1-34), or Parathormon (PTH). The products are administered via injection.
ENTERA BIO LTD
Hadassah / Jerusalem Bio, Park, 5th Floor
JERUSALEM 9112002 IL
CEO: Spiros Jamas
Employees: 18
Company Website: https://enterabio.com/
Investor Relations: http://investors.enterabio.com/
Phone: 97225327151
The current stock price of ENTX is 2.28 USD. The price decreased by -5% in the last trading session.
The exchange symbol of ENTERA BIO LTD is ENTX and it is listed on the Nasdaq exchange.
ENTX stock is listed on the Nasdaq exchange.
7 analysts have analysed ENTX and the average price target is 10.2 USD. This implies a price increase of 347.37% is expected in the next year compared to the current price of 2.28. Check the ENTERA BIO LTD stock analysts ratings, price target forecast and up-and down grades for more detailed information.
ENTERA BIO LTD (ENTX) has a market capitalization of 103.56M USD. This makes ENTX a Micro Cap stock.
ENTERA BIO LTD (ENTX) currently has 18 employees.
ENTERA BIO LTD (ENTX) has a support level at 1.66 and a resistance level at 2.41. Check the full technical report for a detailed analysis of ENTX support and resistance levels.
The Revenue of ENTERA BIO LTD (ENTX) is expected to decline by -100% in the next year. Check the estimates tab for more information on the ENTX EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ENTX does not pay a dividend.
ENTERA BIO LTD (ENTX) will report earnings on 2025-05-09, after the market close.
ENTERA BIO LTD (ENTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.25).
The outstanding short interest for ENTERA BIO LTD (ENTX) is 0.22% of its float. Check the ownership tab for more information on the ENTX short interest.
ChartMill assigns a technical rating of 6 / 10 to ENTX. When comparing the yearly performance of all stocks, ENTX is one of the better performing stocks in the market, outperforming 79% of all stocks.
ChartMill assigns a fundamental rating of 3 / 10 to ENTX. While ENTX has a great health rating, there are worries on its profitability.
Over the last trailing twelve months ENTX reported a non-GAAP Earnings per Share(EPS) of -0.25. The EPS increased by 19.35% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -101.61% | ||
ROE | -118.08% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 83% to ENTX. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of -124.4% and a revenue growth -100% for ENTX